Agenus | AGEN - Ebitda


Agenus reported $-10.11M in EBITDA for its fiscal quarter ending in March of 2025.





Ebitda Change Date
AbbVie USD 6.91B 3.22B Jun/2026
Agenus USD -10.11M 19.02M Mar/2025
Amgen USD 5.8B 1.25B Sep/2026
AstraZeneca USD 7.46B 2.3B Sep/2026
Bristol-Myers Squibb USD 3.48B 1.6B Sep/2026
Celldex Therapeutics USD -79.72M 3.86M Jun/2026
CSL USD 3.13B 1.17B Dec/2025
Eli Lilly USD 9.46B 3.54B Sep/2026
Gilead Sciences USD -9.31B 12.82B Jun/2026
GlaxoSmithKline GBP 3.51B 734M Jun/2026
Glaxosmithkline GBP 2.93B 154M Sep/2026
Incyte USD 778.57M 410.6M Jun/2026
Intrexon USD -24.7M 2.92M Jun/2024
J&J USD 8.99B 721M Jun/2026
Jiangsu Hengrui CNY 2.78B 379.11M Sep/2026
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024
MacroGenics USD -64.54M 34.34M Jun/2026
Merck EUR 1.6B 69M Jun/2026
Merck USD 1.42B 2.97B Jun/2026
Northwest Biotherapeutics USD -13.41M 232K Sep/2023
Novartis USD 8.62B 2.14B Sep/2026
Novavax USD 19.36M 190.79M Dec/2025
Pfizer USD 6.36B 350M Sep/2026
Regeneron Pharmaceuticals USD 1.66B 695.2M Jun/2026
Rigel Pharmaceuticals USD -4.17M 798K Sep/2023
Veracyte USD 41.24M 2.72M Sep/2026